| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
Bacterial DNA (minor groove binding). Topoisomerases (dual-action inhibition).
|
|---|---|
| ln Vitro |
MGB-BP-3 demonstrates potent in vitro activity against a broad range of multi-resistant Gram-positive pathogens, with minimum inhibitory concentration (MIC) values superior to vancomycin. It exhibits rapid bactericidal activity by binding to the minor groove of bacterial DNA, disrupting essential processes such as DNA replication and transcription. The compound shows potent activity against Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococci (VRE).
|
| ln Vivo |
MGB-BP-3 has demonstrated in vivo efficacy in preclinical models of C. difficile infection. In Phase II clinical trials, MGB-BP-3 demonstrated a 100% initial cure rate and a 95% sustained cure rate, with minimal recurrence and preservation of gut microbiota. The compound is currently in late-stage clinical development for the treatment of recurrent CDI.
|
| Enzyme Assay |
The in vitro antibacterial activity is assessed using standard broth microdilution methods according to CLSI guidelines. MGB-BP-3 is serially diluted in cation-adjusted Mueller-Hinton broth in 96-well microtiter plates. Bacterial inoculum (approximately 5 × 10^5 CFU/mL) is added to each well. Plates are incubated at 35°C for 18-24 hours. The minimum inhibitory concentration (MIC) is determined as the lowest concentration that inhibits visible bacterial growth. Time-kill kinetics are performed by sampling at various time points (0, 1, 2, 4, 6, 24 h) and plating for viable colony counts.
|
| Cell Assay |
In vitro cellular assays are performed using cultured mammalian cell lines (e.g., Caco-2 intestinal epithelial cells) to assess compound cytotoxicity and epithelial barrier integrity. Cells are seeded in 96-well plates and incubated with MGB-BP-3 at concentrations ranging from 0.1 to 100 µM for 24-72 hours. Cell viability is measured using MTT or resazurin-based assays. Additionally, the compound's effect on bacterial DNA replication can be assessed in cell-free systems using purified bacterial DNA and replication proteins, or by measuring incorporation of radiolabeled nucleotides into nascent DNA.
|
| Animal Protocol |
In vivo efficacy is evaluated in a hamster model of C. difficile infection. Golden Syrian hamsters are pretreated with clindamycin to disrupt the normal gut microbiota, then challenged with C. difficile vegetative cells or spores. MGB-BP-3 is administered orally at various doses (e.g., 10-50 mg/kg) starting 24 hours post-infection. Animals are monitored for survival, weight loss, and clinical signs of disease for up to 7-14 days. Fecal samples are collected for C. difficile culture and toxin detection. The primary endpoint is survival rate, with secondary endpoints including recurrence rate and gut microbiota composition analysis.
|
| ADME/Pharmacokinetics |
MGB-BP-3 has a molecular weight of 631.7 g/mol and molecular formula C36H37N7O4. It is soluble in DMSO and should be stored as a solid powder at 0-4°C for short-term or -20°C for long-term storage. The compound is stable under dry, dark conditions. Oral bioavailability and half-life data are being evaluated in ongoing clinical trials. In Phase II studies, the compound demonstrated favorable pharmacokinetic properties with minimal systemic absorption, allowing for targeted activity in the gastrointestinal tract.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available for MGB-BP-3. However, the compound has been reported to preserve gut microbiota and cause minimal recurrence in clinical trials. Preclinical toxicology studies would typically include assessment of genotoxicity (Ames test, micronucleus assay), cardiac safety (hERG channel inhibition), and repeated-dose toxicity in rodents and non-rodents. The compound is for research use only and not for human therapeutic use outside of clinical trials.
|
| References |
Description: MGB-BP-3 is a DNA intercalating drug potentially for the treatment of clostridium difficile infections. |
| Additional Infomation |
MGB-BP-3 is being studied in the clinical trial NCT02518607 (Safety, blood levels and efficacy of MGB-BP-3).
MGB-BP-3 is a first-in-class S-MGB antibiotic in late-stage clinical development for recurrent C. difficile infection. It has demonstrated 100% initial cure rate and 95% sustained cure rate in Phase II trials. The compound's unique multi-target mechanism minimizes the risk of resistance development. Its molecular structure includes a bis-benzimidazole core that facilitates minor groove binding. MGB-BP-3 is supplied as a research compound and is not yet approved by regulatory authorities for clinical use. |
| Molecular Formula |
C36H37N7O4
|
|---|---|
| Molecular Weight |
631.7235
|
| Exact Mass |
631.29
|
| CAS # |
1000277-08-6
|
| PubChem CID |
23730143
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
770.2±60.0 °C at 760 mmHg
|
| Flash Point |
419.6±32.9 °C
|
| Vapour Pressure |
0.0±2.6 mmHg at 25°C
|
| Index of Refraction |
1.664
|
| LogP |
2.44
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
47
|
| Complexity |
1090
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN1C=C(C=C1C(=O)NC2=CN(C(=C2)C(=O)NCCN3CCOCC3)C)NC(=O)C4=CC=C(C=C4)/C=C/C5=CC6=CC=CC=C6N=C5
|
| InChi Key |
OEKXCVYZBVOWBR-BQYQJAHWSA-N
|
| InChi Code |
InChI=1S/C36H37N7O4/c1-41-24-30(20-32(41)35(45)37-13-14-43-15-17-47-18-16-43)40-36(46)33-21-29(23-42(33)2)39-34(44)27-11-9-25(10-12-27)7-8-26-19-28-5-3-4-6-31(28)38-22-26/h3-12,19-24H,13-18H2,1-2H3,(H,37,45)(H,39,44)(H,40,46)/b8-7+
|
| Chemical Name |
(E)-1-methyl-4-(1-methyl-4-(4-(2-(quinolin-3-yl)vinyl)benzamido)-1H-pyrrole-2-carboxamido)-N-(2-morpholinoethyl)-1H-pyrrole-2-carboxamide
|
| Synonyms |
MGB-BP-3 MGBBP3 MGB BP 3
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~197.87 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5830 mL | 7.9149 mL | 15.8298 mL | |
| 5 mM | 0.3166 mL | 1.5830 mL | 3.1660 mL | |
| 10 mM | 0.1583 mL | 0.7915 mL | 1.5830 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
